Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Access to Document

@article{84704b12d15245feaed5d7cb4a021f5e,

title = "Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma",

author = "Tomer Meirson and Victoria Neiman and Michal Sternschuss and Gal Markel and Tannock, \{Ian F.\}",

year = "2022",

month = nov,

doi = "10.1016/s1470-2045(22)00629-5",

language = "אנגלית",

volume = "23",

pages = "e489",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

AU - Meirson, Tomer

AU - Neiman, Victoria

AU - Sternschuss, Michal

AU - Markel, Gal

AU - Tannock, Ian F.

PY - 2022/11

Y1 - 2022/11

UR - https://www.scopus.com/pages/publications/85141286712

U2 - 10.1016/s1470-2045(22)00629-5

DO - 10.1016/s1470-2045(22)00629-5

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 36328018

AN - SCOPUS:85141286712

SN - 1470-2045

VL - 23

SP - e489

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -